多柔比星心肌毒性监测及预防研究的进展  

Research progress for monitoring and prevention of doxorubicin cardiotoxicity

作　　者：樊凌云[1] 阮毅燕[1] 

机构地区：[1]广西壮族自治区妇幼保健院儿科,广西南宁530000

出　　处：《心血管康复医学杂志》2014年第3期355-358,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：多柔比星(doxorubicin,DOX)属蒽醌类抗肿瘤抗生素,是目前临床应用最广泛的抗癌药之一,但对心脏有毒性作用,怎样减轻其心脏毒性,仍然是目前研究的热门问题。本文就DOX心脏毒性的监测及预防进行综述。Doxorubicin （DOX）belongs to anthraquinone anti-tumor antibiotics,which is now one of most widely used anti-cancer drugs in clinic,but it possesses cardiotoxicity.How to reduce its cardiotoxicity is still a hot problem in current research.This article made an overview for monitoring and prevention of DOX cardiotoxicity.

关 键 词：心肌 毒性作用 多柔比星 

分 类 号：R542.2[医药卫生—心血管疾病]